Introduction
============

Esophageal cancer is one of the most common malignancies worldwide. It is the leading cancer-related cause of deaths in the People's Republic of China. Esophageal squamous cell carcinoma (ESCC) accounts for 80% of all esophageal cancer in eastern Asia. The incidence of esophageal cancer continued to rise in past decades, likely as a result of increased public awareness and implementation of screening programs. Early-stage (~P~T~1--3~N~0~M~0~) ESCC forms a subset of relatively favorable prognosis, with a low incidence of distant organ metastasis, local recurrence, and death.[@b1-ott-8-3153] Adjuvant chemoradiotherapy is not routinely recommended in this population. The mainstay of treatment of ~P~T~1--3~N~0~M~0~ ESCC is curative resection. However, only approximately 50%--60% of these tumors can be cured by surgery alone.[@b2-ott-8-3153] Recently, the role of adjuvant chemoradiotherapy for PT~1--3~N~0~M~0~ ESCC has been justified in some high-risk patients, with decisions directed by the presence of adverse or clinicopathological features, such as close or involved surgical margin, tumor length, lymphovascular involvement, and extracapsular spread.[@b3-ott-8-3153]--[@b5-ott-8-3153] Besides the economic constraints that health-care systems are increasingly facing, oncologists also need to carefully weigh the benefits and risks of future treatment. Adjuvant chemoradiotherapy is associated with significant side effects and morbidity.[@b6-ott-8-3153] In view of this, the risk of recurrence and the potential benefit of adjuvant chemoradiotherapy have to be evaluated to select the proper patients with ~P~T~1--3~N~0~M~0~ ESCC.

Perineural invasion (PNI) is a pathological process characterized by cancer cells surrounding nerve fibers and entering the perineurium or neural fascicles. It is an under-recognized route of metastatic spread, which can occur in the absence of lymphatic or vascular involvement. Metastasis, the ability of cancer cells to spread from a primary site to form a new tumor at distant sites, is the main reason for death caused by cancer. Therefore, it is reported that PNI was a rucial route for the local spread and distant metastasis of cancer, associated with poor prognosis, especially in prostate cancer[@b7-ott-8-3153],[@b8-ott-8-3153] and pancreatic carcinoma.[@b9-ott-8-3153],[@b10-ott-8-3153]

Methods
=======

Patients
--------

A total of 148 consecutive patients who underwent curative surgery for ~P~T~1--3~N~0~M~0~ ESCC were diagnosed and treated in Zhejiang Cancer Hospital, Hangzhou, People's Republic of China, between October 2006 and December 2009. The selective criteria included the following: newly confirmed to have ESCC and had not received treatment previously; a negative incised margin; no distant metastasis; postoperative survival expectancy was longer than 3 months. Clinicopathological information such as age, sex, resection type, tumor location, histopathology, tumor stage, tumor length, lymphatic vessel invasion, resection margins, recurrence, and survival was obtained from patient charts.

Pathological evaluation
-----------------------

A thorough histopathological examination of the surgical excision specimen stained with hematoxylin and eosin (H&E) was performed to document all foci of PNI on each 5 µm thick slide if present. PNI was defined as cancer cells surrounding at least one-third of the nerve without invading through the nerve sheath, as well as tumor cells within any of the three layers of the nerve sheath. Histopathological slides were independently reviewed by two pathologists who were blinded to other information of the patients.

Follow-up
---------

All patients received standardized follow-up at 3-month intervals for the first 2 years after operation, at 6-month intervals in the third year, and yearly thereafter. Evaluation comprised a physical examination, upper gastrointestinal endoscopy, complete blood count, chest and abdomen computed tomography. Distant metastasis-free survival (DMFS) covering the date of definitive surgery to the date of distant metastasis was diagnosed. Overall survival (OS) was calculated as the time from the date of surgery to death or censoring.

Statistical analysis
--------------------

All statistical calculations were performed using SPSS 13.0 for Windows (SPSS Inc., Chicago, IL, USA). The relationship between PNI positivity and the other clinicopathological factors was analyzed by the chi-square test. DMFS and OS were analyzed by Kaplan--Meier analysis with log-rank test. Multivariate Cox proportional hazards regression model with forward stepwise approach was constructed to identify independent prognostic factors. A 95% confidence interval (95% CI) was used to quantify the relationship between survival time and each independent factor. All *P*-values were two-sided in the tests. The values of *P*\<0.05 were considered statistically significant.

Results
=======

A total of 148 patients who had undergone curative resection for PT~1--3~N~0~ ESCC were retrospectively analyzed; eleven patients were women and 137 were men. The baseline characteristics of these ESCC patients are summarized in [Table 1](#t1-ott-8-3153){ref-type="table"}. The median age was 58 years, (range: 38--75 years). In terms of the new American Joint Committee on Cancer tumor node metastasis staging system, there were 35 (23.6%) T~1~, 36 (24.3%) T~2~, and 77 (52.1%) T~3~. PNI was detected as positive in 37 of the 148 patients (25.0%). The relationship between PNI and clinicopathological factors is shown in [Table 1](#t1-ott-8-3153){ref-type="table"}. There was no significant association between the presence of PNI and patients' sex, age, smoking status, alcohol status, tumor cell differentiation, and tumor length (*P*\>0.05). The depth of invasion (~P~T stage) was closely associated with the PNI positivity (*P*\<0.001).

At the median follow-up of 30 months (range: 4--96 months), the 5-year DMFS rate and OS rate were 56.8% and 66.4%, respectively. For patients who had PNI negativity, the 5-year DMFS rate and OS rate were 62.3% and 74.3%, respectively. For the PNI-positive patients, the 5-year DMFS rate and OS rate were 37.2% and 31.3%, respectively. Then, the prognostic significance of PNI and other clinicopathological variables was examined using univariate regression models (shown in [Table 2](#t2-ott-8-3153){ref-type="table"}). The presence of PNI was significantly associated with DMFS in the univariate analysis (*P*=0.009, [Figure 1](#f1-ott-8-3153){ref-type="fig"}). The likelihood of developing distant metastasis was 2.34-fold greater in patients with PNI-positive tumors than in those with PNI-negative tumors. Similar results were also observed for the 5-year OS (81.2% vs 52.5%, *P*\<0.001, [Figure 2](#f2-ott-8-3153){ref-type="fig"}). Furthermore, we performed multivariate analysis with Cox regression method in order to evaluate the prognostic significance of PNI and the other clinicopathological factors. [Table 3](#t3-ott-8-3153){ref-type="table"} shows the results of multivariate analysis in all patients. Multivariate analysis indicated that the positivity of PNI was an independent prognostic factor. Patients with PNI had an elevated risk of distant metastasis and death compared to those without PNI. The hazard ratio was 2.35 (95% CI: 1.04--5.29) for metastasis and 3.56 (95% CI: 1.62--7.84) for death. These analyses were adjusted for patients' age, sex, smoking status, and ~P~T stage.

Discussion
==========

In this study, surgical specimens were stained with H&E to determine the positivity of PNI and analyze treatment decisions in relation to PNI status in ~P~T~1--3~N~0~M~0~ ESCC. Despite the progression of adjuvant treatment, ~P~T~1--3~N~0~M~0~ ESCC is always excluded from the recommendation for adjuvant chemoradiotherapy in the People's Republic of China. However, our study clearly identified a worse prognostic subgroup in PT1--3N0M0 ESCC. According to the multivariate analysis, PNI was the only one independent prognostic factor. ~P~T~1--3~N~0~M~0~ ESCC with positive PNI exhibited a markedly poorer prognosis and a higher rate of distant metastasis, suggesting an indication for additional adjuvant chemotherapy.

In this study, we found that 25.0% of the cases were PNI-positive, an intermediate percentage between the values reported in the literature, which range from 5% to 47.7%.[@b11-ott-8-3153]--[@b13-ott-8-3153] The staining methods, measurement techniques, differences in histological types, and PNI definition may contribute to this discrepancy, which leads to difficult comparison across different studies. Actually, it also limits the clinical application of PNI. In the study, we used the broader definition as some other investigator described:[@b13-ott-8-3153],[@b14-ott-8-3153] cancer cells surrounding at least one-third of the nerve without invading through the nerve sheath, as well as tumor cells within any of the three layers of the nerve sheath. A study of ESCC patients undergoing radical esophagectomy found PNI to be associated with markers of aggressive and advanced disease.[@b15-ott-8-3153] Chen et al[@b13-ott-8-3153] found that PNI in ESCC was significantly correlated with tumor differentiation, infiltration depth, PN classification, and stage (*P*\<0.05). Several other authors published similar results.[@b11-ott-8-3153],[@b16-ott-8-3153] In our study, PNI was not associated with other markers of cancer stage or aggressiveness except ~P~T stage (*P*\<0.001). Thus, PNI seems to be unrelated to other prognostic factors, such as tumor cell differentiation and tumor length. Furthermore, the 5-year DMFS rate was 37.2% in PT1--3N0M0 ESCC patients with PNI, which was significantly lower than the rate (62.3%) in the patients without PNI. Therefore, we speculated that PNI represents a distinct metastatic process, not simply tumor cell migration. This provides strong evidence for performing adjuvant chemotherapy at the presence of PNI in ~P~T~1--3~N~0~M~0~ ESCC.

According to the National Comprehensive Cancer Network Guidelines^®^, PNI is considered to be one of the high-risk features in esophagus carcinoma, and chemoradiation therapy was recommended for patients with high-risk features. Recently, Ning et al[@b17-ott-8-3153] retrospectively reviewed 243 locally advanced ESCC patients who underwent curative resection. PNI was identified in 22.2% (54/243) patients. In PNI-positive ESCC patients, the median disease-free survival time and OS time were longer in patients with postoperative radiotherapy than patients without postoperative radiotherapy. However, there were no statistical differences. In our study, only six patients with PNI received adjuvant chemotherapy, and four patients received adjuvant chemoradiotherapy. Until now, these patients survived without distant metastasis. It seems that adjuvant chemoradiotherapy can prolong disease-free survival and OS time in PNI-positive ESCC patients. Future prospective study is needed to confirm the function of additional adjuvant chemoradiotherapy in PNI ESCC patients.

Limitations
===========

The major limitations of this study are small sample size and relatively short follow-up time. The small number of patients in the subgroup with PNI-positive tumors also limits the subgroup analysis. In addition, the retrospective nature of our study could be considered another significant limitation, which may have influenced this result. However, although our results should be confirmed by prospective studies, we believe that our results contribute to the literature because of the inclusion of only patients with early-stage ESCC. Finally, how PNI influences distant metastasis also remains unclear. The mechanism of nerve--tumor interaction in the perineural microenvironment needs to be understood to help develop novel treatment strategies in the PNI-related metastasis pathway to decrease recurrence.

Conclusion
==========

In summary, this study confirmed the intermediate incidence of PNI in ~P~T~1--3~N~0~M~0~ ESCC. PNI is related to T stage and distant metastasis, postoperatively. Furthermore, PNI contributes important additional information as an independent prognostic indicator for DMFS and OS. Large-scale and well-designed prospective cohort studies will be needed to elucidate how a quantification of PNI status may be used to determine the need for postoperative adjuvant chemoradiotherapy.
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![DMFS curve subdivided by PNI in ~P~T~1--3~N~0~ ESCC.\
**Note:** Patients with PNI-positive tumors showed significantly poorer DMFS than those with PNI-negative tumors (*P*=0.009, log-rank test).\
**Abbreviations:** DMFS, distant metastasis-free survival; PNI, perineural invasion; ESCC, esophageal squamous cell carcinoma.](ott-8-3153Fig1){#f1-ott-8-3153}

![OS curve subdivided by PNI in ~P~T~1--3~N~0~ ESCC.\
**Note:** Patients with PNI-positive tumors showed significantly poorer OS than those with PNI-negative tumors (*P*\<0.001, log-rank test).\
**Abbreviations:** PNI, perineural invasion; OS, overall survival; ESCC, esophageal squamous cell carcinoma.](ott-8-3153Fig2){#f2-ott-8-3153}

###### 

The relationship between PNI and clinicopathological factors in patients with ~P~T~1--3~N~0~M~0~ ESCC who underwent curative resection

  Characteristics         Total   PNI (n, %)   *P*-value   
  ----------------------- ------- ------------ ----------- --------
  Sex                                                      
   Male                   137     101 (73.7)   36 (26.3)   0.205
   Female                 11      10 (90.9)    1 (9.1)     
  Age, years                                               
   \<65                   120     92 (76.7)    28 (23.3)   0.332
   ≥65                    28      19 (67.9)    9 (32.1)    
  Smoking status                                           
   Never                  23      19 (82.6)    4 (17.4)    0.359
   Ever                   125     92 (73.6)    33 (26.4)   
  Alcohol status                                           
   Never                  49      38 (77.6)    11 (22.4)   0.614
   Ever                   99      73 (73.7)    26 (26.3)   
  Differentiation                                          
   Well                   24      18 (75.0)    6 (25.0)    0.444
   Moderate               98      76 (77.6)    22 (22.4)   
   Poor                   26      17 (65.4)    9 (34.6)    
  Tumor length                                             
    ≤3 cm                 55      45 (81.8)    10 (18.2)   0.158
   \>3 cm                 93      66 (71.0)    27 (29.0)   
  T stage                                                  
   T~1--2~                71      66 (93.0)    5 (7.0)     ,0.001
  T~3~                    77      45 (58.4)    32 (41.6)   
  Lymphatic involvement                                    
   No                     139     105 (75.5)   34 (24.5)   0.551
   Yes                    9       6 (66.7)     3 (33.3)    

**Abbreviations:** PNI, perineural invasion; ESCC, esophageal squamous cell carcinoma.

###### 

DMFS and OS rates among 148 ~P~T~1--3~N~0~M~0~ ESCC patients who underwent curative resection

  Characteristics         DMFS   OS              
  ----------------------- ------ ------- ------- ---------
  Sex                                            
   Male                   55.2   0.293   64.6    0.118
   Female                 80.0           100.0   
  Age, years                                     
   \<65                   59.8   0.412   70.6    0.652
   ≤65                    47.3           47.5    
  Smoking status                                 
   Never                  36.0   0.623   67.5    0.500
   Ever                   58.1           66.1    
  Alcohol status                                 
   Never                  55.5   0.643   80.4    0.050
   Ever                   56.9           61.2    
  Differentiation                                
   Well                   45.7   0.653   62.4    0.548
   Moderate               57.9           72.1    
   Poor                   60.7           48.8    
  Tumor length                                   
    ≤3 cm                 51.0   0.351   67.7    0.588
   \>3 cm                 77.0           60.7    
  T stage                                        
   T~1--2~                57.2   0.212   81.2    0.012
   T~3~                   57.0           52.5    
  Lymphatic involvement                          
   Negative               59.5   0.164   67.2    0.347
   Positive               25.4           55.6    
  PNI                                            
   Negative               62.3   0.009   78.7    \<0.001
   Positive               37.2           31.3    

**Abbreviations:** DMFS, distant metastasis-free survival; OS, overall survival; PNI, perineural invasion; ESCC, esophageal squamous cell carcinoma.

###### 

The relationship between PNI and survival in patients with ~P~T~1--3~N~0~ ESCC using Cox proportional hazards model analysis

                  Crude HR   95% CI       *P*-value   Adjusted HR   95% CI       *P*-value
  --------------- ---------- ------------ ----------- ------------- ------------ -----------
  DMFS                                                                           
   PNI negative   1                                   1                          
   PNI positive   2.34       1.21--4.51   0.011       2.35          1.04--5.29   0.039
  OS                                                                             
   PNI negative   1                                   1                          
   PNI positive   3.86       2.00--7.43   ,0.001      3.56          1.62--7.84   0.002

**Abbreviations:** PNI, perineural invasion; ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; CI, confidence interval; DMFS, distant metastasis-free survival; OS, overall survival.
